Our Journey

1993

Therapeutic Goods Administration (TGA) Australia audits manufacturing facility at Mega.

1994

Acquired the MedicraftsTM brand and associated trademarks for a range of products; it helped in growing our branded products and its market acceptance.

Soi 6 manufacturing facility received GMP certification from the Australian TGA.

1995-1996

Established operations in Myanmar (’95), Vietnam (’95) and Cambodia (’96) to market and sell our own brands and developed our distribution business as well.

Added 3 more machines to our capacity.

1997

We become the first pharmaceutical company in Thailand to receive the ISO 9002 certification.

2000

Launched our own brands into developing markets including the Commonwealth of Independent States and countries in Africa and the Middle East(Kenya, Tanzania and Uganda).

2001

Mega We careTM registered as trademark.

Our manufacturing facility in Soi 6 obtained GMP certification from the German health authority, the district government of Arnsberg.

First Thai pharmaceutical company to export nutraceutical and pharmaceutical products to Germany Initiate Brand business in Yemen & Malaysia.

2002

Started manufacturing facility in Dandenong, Melbourne, Australia and received a TGA licence for the operations.

Initiate Brand business in Nigeria & Ukraine.

2003

Initiate Brand business in ,Kazakhstan,Azerbaijan and Singapore.

2004

Our Soi 6 manufacturing facility received GMP certificate from Uganda, Nigeria, Tanzania and Danish health authorities.

2005

Changed our company name from “Medicap Limited” to “Mega Lifesciences Company Limited”.

2006

Ministry of Health of Yemen and Ukraine awarded the GMP certification to our Soi 6 manufacturing facility in Thailand.

Mega Lifesciences Company Limited, Myanmar became the first distribution and logistics company in Myanmar to receive ISO 9001 certification.

2008

Our 2nd manufacturing facility was established in Soi 8 in samut prakran, Thailand for manufacturing tablets, hard capsules and packages commencing next year.

GMP certifications for our Soi 6, Thailand and Australian manufacturing facilities from United Arab Emirates ministry of health.

Initiate Brand business in Uzbekistan and Ghana.

2009

We received GMP certification for our Soi 6 manufacturing facility from the Oman Ministry of Health.

In the same year, we received GMP certification for our Soi 8 manufacturing facility from: (i) the District Government of Arnsberg in Germany; (ii) the Thai FDA; and (iii) the Australian TGA.

Initiate Brand business in Peru.

2010

We registered “Maxxcare” as a trademark in 2010. MaxxcareTM is the primary trademark for our distribution business.

GMP certifications for our Soi 8 manufacturing facility from the Ukrainian Ministry of Health.

Both of our manufacturing facilities in Thailand also received certification from the Ethiopian Drug and Administration Authority

Replaced existing eight production lines and added two more production lines to our first manufacturing facility in Samut Prakarn, Thailand. Annual capacity increased to 2.1 billion.

2012

GMP certification for our Soi 6 manufacturing facility from the Ministry of Health of Sudan.

Our Soi 8 manufacturing facility in Thailand received GMP certification from the Ministry of Health of Yemen.

In addition, both of our manufacturing facilities in Thailand received GMP certification from the Ministry of Health of Peru.

• We received the Taxpayers’ Recognition Award 2011, an award recognizing taxpayer responsibility, from the Thai Revenue Department in recognition of our being a good corporate citizen with good corporate governance and best practices in paying taxes.
• Acquired the EugicaTM brand, intellectual property and title documents.
• According to IMS Health data as of June 2013, a number of our branded products were ranked number one in their respective market categories in 2012.
• Commenced work on extension of the second facility to include new PD lab ,manufacturing and packing area.Commenced work on new manufacturing facility in Australia.

2013

We received GMP certifications from the Ugandan National Drug Authority and the United Arab Emirates’ Ministry of Health for our Soi 8 manufacturing facility in Thailand.

We relocated our manufacturing facility in Australia from Dandenong to a newly constructed manufacturing facility in Pakenham, Melbourne (“Pakenham Facility”), also received GMP certification from the Australian TGA.

• Production capacity at Australia to increase to 250 million tablets,30 million hardgel and 800 metric tonnes of powder handling capacity per annum. For Tablets, hard gel, capsule & powder.
• 4000 members make up the global mega family.
• Transformed our Company into a public company, we got listed in Thailand Stock exchange in November 2013 and changed our name to Mega Lifesciences Public Company Limited.

2016

The journey of expansion to human wellness continues.